NO990076L - FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon - Google Patents

FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon

Info

Publication number
NO990076L
NO990076L NO990076A NO990076A NO990076L NO 990076 L NO990076 L NO 990076L NO 990076 A NO990076 A NO 990076A NO 990076 A NO990076 A NO 990076A NO 990076 L NO990076 L NO 990076L
Authority
NO
Norway
Prior art keywords
thiazolidinone
pct
administration
treating
neurodegenerative conditions
Prior art date
Application number
NO990076A
Other languages
English (en)
Other versions
NO990076D0 (no
Inventor
Richard Thomas Carroll
Richard Dennis Dyer
Lillian Jane Robichaud
Brenda De Rae Shivers
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO990076D0 publication Critical patent/NO990076D0/no
Publication of NO990076L publication Critical patent/NO990076L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
NO990076A 1996-07-11 1999-01-08 FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon NO990076L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2157196P 1996-07-11 1996-07-11
PCT/US1997/011586 WO1998002160A1 (en) 1996-07-11 1997-07-01 Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone

Publications (2)

Publication Number Publication Date
NO990076D0 NO990076D0 (no) 1999-01-08
NO990076L true NO990076L (no) 1999-01-08

Family

ID=21804973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990076A NO990076L (no) 1996-07-11 1999-01-08 FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon

Country Status (22)

Country Link
US (1) US5912259A (no)
EP (1) EP0914122B1 (no)
JP (1) JP2001508028A (no)
KR (1) KR20000023683A (no)
CN (1) CN1145481C (no)
AT (1) ATE250416T1 (no)
AU (1) AU726664B2 (no)
BR (1) BR9710467A (no)
CA (1) CA2255073A1 (no)
CO (1) CO4940509A1 (no)
DE (1) DE69725147T2 (no)
DK (1) DK0914122T3 (no)
ES (1) ES2205247T3 (no)
HR (1) HRP970362A2 (no)
IL (1) IL127487A (no)
NO (1) NO990076L (no)
NZ (1) NZ332763A (no)
PL (1) PL331049A1 (no)
PT (1) PT914122E (no)
TR (1) TR199900040T2 (no)
WO (1) WO1998002160A1 (no)
ZA (1) ZA976142B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104423A2 (en) * 2002-06-11 2003-12-18 Roy Ogle Meningeal-derived stem cells
US20110104296A1 (en) * 2008-05-08 2011-05-05 Dipak Kumar Sarkar Endorphin Therapy Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
ZA902520B (en) * 1989-04-07 1991-12-24 Lilly Co Eli Aryl-substituted rhodanine derivatives
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
EP0722729A3 (en) * 1995-01-23 1997-11-26 Eli Lilly And Company Aryl-substituted rhodanines for treating multiple sclerosis
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

Also Published As

Publication number Publication date
CN1145481C (zh) 2004-04-14
CN1223582A (zh) 1999-07-21
EP0914122A1 (en) 1999-05-12
TR199900040T2 (xx) 1999-04-21
NO990076D0 (no) 1999-01-08
DE69725147T2 (de) 2004-07-22
PT914122E (pt) 2003-12-31
IL127487A (en) 2002-04-21
CA2255073A1 (en) 1998-01-22
AU726664B2 (en) 2000-11-16
WO1998002160A1 (en) 1998-01-22
CO4940509A1 (es) 2000-07-24
DK0914122T3 (da) 2003-12-22
JP2001508028A (ja) 2001-06-19
ATE250416T1 (de) 2003-10-15
HRP970362A2 (en) 1998-04-30
HK1020533A1 (en) 2000-05-12
IL127487A0 (en) 1999-10-28
PL331049A1 (en) 1999-06-21
EP0914122B1 (en) 2003-09-24
BR9710467A (pt) 1999-08-17
US5912259A (en) 1999-06-15
AU3649197A (en) 1998-02-09
ZA976142B (en) 1998-02-02
NZ332763A (en) 2000-07-28
DE69725147D1 (de) 2003-10-30
KR20000023683A (ko) 2000-04-25
ES2205247T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
CA2168829A1 (en) Paroxetine hydrochloride anhydrate forms a,b,c and d
DE69709070D1 (de) Verbrückte zyklische aminosäuren als pharmazeutische mittel
PT1293207E (pt) Utilização de ritonavir (abt-538) para melhoria da farmacocinética de drogas metabolizadas por citocromo p450 num método de tratamento da sida
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
IL125544A0 (en) Novel substituted cyclic amino acids as pharmaceutical agents
CA2029065A1 (en) Method of treating anxiety related disorders using sertraline
ATE193442T1 (de) 3,4-diarylchromane zur behandlung von dermatitis
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
NO990076L (no) FremgangsmÕte for behandling og forhundring av nevrodegenerative tilstander ved administrasjon av tiazolidinon
EP1447090B8 (de) Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen
SE9302218D0 (sv) New use
AU6053496A (en) The use of sertraline to treat post myocardial infarction patients
CA2158173A1 (en) Method of treating addictive behaviors
ATE245982T1 (de) Verwendung von 2-amino-6- trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
SE9501773D0 (sv) New use
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.
NO961496L (no) Behandling av allergiske sykdommer med terfenadinkarboksylat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application